Prostate Cancer Discoveries Digest Welcome to your monthly summary of the notable research studies and developments that help provide greater insight into prostate cancer causes, treatments, outcomes, and survivorship. See all Newsletters Jump To Jump To Join the Email List The prostate cancer landscape is rapidly changing. This featured content is meant to provide an update on the latest in diagnosis, treatment, side effect management, and survivorship. ZERO Prostate Cancer does not endorse any particular article or finding that may be featured. Know someone who'd be interested in getting monthly updates on prostate cancer research and other topics? Forward or use our Tell-a-Friend tool to share this email, and tell them to sign up for free at zerocancer.org/newsletters. Treatment Prostate Cancer: Adjuvant Radiotherapy With 6 Months of ADT vs No ADT Metastasis-free survival was not significantly improved with 6 months of ADT v no ADT plus adjuvant radiotherapy. » Full article on The ASCO Post Screening Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer Men living in US counties with a higher prevalence of PSA screening are less likely to have advanced prostate cancer and to die from it. » Full article on JAMA Network Open Survivorship First results from Europa Uomo's innovative study into couples' quality of life A survey of 1,135 caregivers of those diagnosed with prostate cancer found a striking mismatch between the information partners expect and the information given. » Full article on Europa Uomo Treatment Active surveillance yields similar outcomes to prostate cancer treatment, 10-year data show Long-term data recently published in JAMA indicate that active surveillance is an effective alternative to immediate surgery or radiation for patients with favorable-risk prostate cancer. » Full article on Urology Times Treatment 100% BCR-Free at 2 Years: Promising Early Results for High-Risk Prostate Cancer Early data shows great promise for high-risk, localized prostate cancer. » Full article on Targeted Oncology Treatment CRISPR Identifies New Genes as Drivers of Prostate Cancer Metastasis CRISPR (short for "clustered regularly interspaced short palindromic repeats"), technology that research scientists use to selectively modify the DNA of living organisms, has opened potential new avenues for targeted cancer therapies. » Full article on CRISPR Medicine News Treatment Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent AI tool may help doctors better deliver focal therapy and lead to changes in clinical treatment decision-making. » Full article on American Urological Association Journals Survivorship Survival in Patients With De Novo Metastatic Prostate Cancer A cross-sectional study examining US SEER (Surveillance, Epidemiology, and End Results) and VHA (Veterans Health Administration) data showed that the median overall survival in de novo mHSPC has improved significantly in the US from 2000-2019, particularly in patients younger than 70 years. » Full article on JAMA Network Open Treatments FDA awards fast track designation to BNT324/DB-1311 in mCRPC The FDA has granted a fast track designation to a drug candidate for patients with mCRPC whose tumors have progressed on standard systemic therapy. » Full article on Urology Times Diagnostics FDA approves FoundationOneLiquid CDx for niraparib/abiraterone in mCRPC The FDA has approved the liquid biopsy test FoundationOneLiquid CDx for use as a companion diagnostic in identifying patients with BRCA-positive mCRPC who may benefit from treatment with niraparib and abiraterone acetate dual action tablets (Akeega). » Full article on Urology Times ZERO Prostate Cancer provides this information as a service. It is not intended to take the place of medical professionals or the recommendations of your healthcare team. Consult your healthcare team if you have questions about your specific care. Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
The prostate cancer landscape is rapidly changing. This featured content is meant to provide an update on the latest in diagnosis, treatment, side effect management, and survivorship. ZERO Prostate Cancer does not endorse any particular article or finding that may be featured. Know someone who'd be interested in getting monthly updates on prostate cancer research and other topics? Forward or use our Tell-a-Friend tool to share this email, and tell them to sign up for free at zerocancer.org/newsletters. Treatment Prostate Cancer: Adjuvant Radiotherapy With 6 Months of ADT vs No ADT Metastasis-free survival was not significantly improved with 6 months of ADT v no ADT plus adjuvant radiotherapy. » Full article on The ASCO Post Screening Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer Men living in US counties with a higher prevalence of PSA screening are less likely to have advanced prostate cancer and to die from it. » Full article on JAMA Network Open Survivorship First results from Europa Uomo's innovative study into couples' quality of life A survey of 1,135 caregivers of those diagnosed with prostate cancer found a striking mismatch between the information partners expect and the information given. » Full article on Europa Uomo Treatment Active surveillance yields similar outcomes to prostate cancer treatment, 10-year data show Long-term data recently published in JAMA indicate that active surveillance is an effective alternative to immediate surgery or radiation for patients with favorable-risk prostate cancer. » Full article on Urology Times Treatment 100% BCR-Free at 2 Years: Promising Early Results for High-Risk Prostate Cancer Early data shows great promise for high-risk, localized prostate cancer. » Full article on Targeted Oncology Treatment CRISPR Identifies New Genes as Drivers of Prostate Cancer Metastasis CRISPR (short for "clustered regularly interspaced short palindromic repeats"), technology that research scientists use to selectively modify the DNA of living organisms, has opened potential new avenues for targeted cancer therapies. » Full article on CRISPR Medicine News Treatment Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent AI tool may help doctors better deliver focal therapy and lead to changes in clinical treatment decision-making. » Full article on American Urological Association Journals Survivorship Survival in Patients With De Novo Metastatic Prostate Cancer A cross-sectional study examining US SEER (Surveillance, Epidemiology, and End Results) and VHA (Veterans Health Administration) data showed that the median overall survival in de novo mHSPC has improved significantly in the US from 2000-2019, particularly in patients younger than 70 years. » Full article on JAMA Network Open Treatments FDA awards fast track designation to BNT324/DB-1311 in mCRPC The FDA has granted a fast track designation to a drug candidate for patients with mCRPC whose tumors have progressed on standard systemic therapy. » Full article on Urology Times Diagnostics FDA approves FoundationOneLiquid CDx for niraparib/abiraterone in mCRPC The FDA has approved the liquid biopsy test FoundationOneLiquid CDx for use as a companion diagnostic in identifying patients with BRCA-positive mCRPC who may benefit from treatment with niraparib and abiraterone acetate dual action tablets (Akeega). » Full article on Urology Times ZERO Prostate Cancer provides this information as a service. It is not intended to take the place of medical professionals or the recommendations of your healthcare team. Consult your healthcare team if you have questions about your specific care.
Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
